Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis

Clicks: 305
ID: 271536
2000
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #87 of 439 articles by views in The Journal of infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 439 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In experimental visceral leishmaniasis, interleukin (IL)-12 initiates control over Leishmania donovani via Th1 cell activation, interferon (IFN)-gamma secretion, and granuloma formation. Because the leishmanicidal effect of conventional therapy, pentavalent antimony (Sb), also requires T cells and e …
Reference Key
hw2000theinterleukin-12 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Murray HW;Montelibano C;Peterson R;Sypek JP;;
Journal The Journal of infectious diseases
Year 2000
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/11023473
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE Mice animals pubmed abstract nih national institutes of health national library of medicine research support u.s. gov't P.H.S. Inbred BALB C Knockout leishmaniasis h w murray antimony / therapeutic use visceral / drug therapy* pmid:11023473 doi:10.1086/315890 c montelibano j p sypek interferon-gamma / physiology interleukin-12 / physiology* interleukin-4 / physiology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.